Vivoryon Therapeutics N.V. announced that the company's CEO Dr. Ulrich Dauer has informed Vivoryon's Board of Directors that he has decided not to renew his contract as a member of the Company's executive leadership team. As a result of his decision, Dr. Dauer will step down as CEO on expiry of his current contract on the date of the 2024 Annual General Meeting or when the appointment of a suitable successor has been agreed upon. The Board of Directors will initiate a search for Dr. Dauer's successor focused on a seasoned business leader who can continue to create shareholder value and drive advancements to realize the full potential of Vivoryon's approach in Alzheimer's disease and beyond, including varoglutamstat's progress towards market approval.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 EUR | -2.44% | +76.60% | -90.17% |
Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-90.17% | 22.26M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VVY Stock
- News Vivoryon Therapeutics N.V.
- Vivoryon Therapeutics N.V. Announces Resignation of Ulrich Dauer as CEO